Metabolic syndrome. Postprocedural endocrine and metabolic disorders, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Daily intake of 10 grams of chia seeds in the form of tea, At the beginning of the study and at the end of the twelfth week, the patients will be given three days o
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Having the criteria of the Iranian Diabetes Society for the diagnosis of metabolic syndrome
Exclusion criteria
Exclusion criteria: Smoking or alcohol use Suffering from cardiovascular diseases, metabolic diseases, digestive diseases, inflammatory diseases, cancer Use of non-steroidal anti-inflammatory drugs and corticosteroids Pregnancy or breastfeeding in women or use of birth control pills Use of hepatotoxic drugs, hypoglycemic or blood lipid lowering drugs, and calcium channel blockers (CCB) Use of multivitamin and mineral supplements History of weight loss surgery in the last year, weight loss program in the last 3 months History of hypothyroidism and Cushing's syndrome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin resistance. Timepoint: Before the start of the intervention and after the end of the twelfth week. Method of measurement: The measured insulin resistance is calculated using the following formula. HOMA-IR= (fasting insulin × fasting glucose)÷ 405. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting glucose. Timepoint: Before the start of the intervention and the end of the twelfth week. Method of measurement: Serum glucose concentration in fasting state measured by enzymatic method Mg/dl.;Fasting insulin. Timepoint: Before the start of the intervention and the end of the twelfth week. Method of measurement: Serum fasting insulin concentration measured by ELISA µu/ml.;Glycosylated hemoglobin. Timepoint: Before the start of the intervention and the end of the twelfth week. Method of measurement: Glycosylated hemoglobin percentage using the relevant kit.;Leptin. Timepoint: Before the start of the intervention and the end of the twelfth week. Method of measurement: Serum leptin concentration in fasting state.;Adiponectin. Timepoint: Before the start of the intervention and the end of the twelfth week. Method of measurement: Serum adiponectin concentration in fasting state.;Malondialdehyde. Timepoint: Before the start of the intervention and the end of the twelfth week. Method of measurement: Serum malondialdehyde level as an index of lipid peroxidation.;High sensitivity C-reactive protein. Timepoint: Before the start of the intervention and the end of the twelfth week. Method of measurement: Serum concentration of C-reactive protein measured by ELISA method.;Diastolic blood pressure. Timepoint: Before the start of the intervention and the end of the twelfth week. Method of measurement: Diastolic blood pressure measured with blood pressure device mmHg.;Systolic blood pressure. Timepoint: Before the start of the intervention and the end of the twelfth week. Method of measurement: Systolic blood pressure measured with blood pressure device mmHg.;Anthropometric indices(height, weight, waist circumference, body mass index). Timepoint: Before the start of the intervention and the end of the twelfth week. Method of measurement: Height: the height of the person in a standing position without shoes with an accuracy of 0.5 cm, weight: the person's weight in kilogram | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLeila Mirzaei
Ahvaz University of Medical Sciences
Outcome results
None listed